Differentiating Factors of Abemaciclib Among the CDK 4/6 Inhibitors for Breast Cancer

May 30, 2017
Hope S. Rugo, MD

Hope S. Rugo, MD, discusses the differentiating factors of abemaciclib among the CDK 4/6 inhibitors for breast cancer treatment.